Julian S Gangolli Takes A Bullish Stance, Acquiring Krystal Biotech Stock Options Worth $6K

Disclosed in a recent SEC filing, Julian S Gangolli, Director at Krystal Biotech KRYS, made a strategic move by acquiring company stock options on June 30,.

What Happened: In a Form 4 filing with the U.S. Securities and Exchange Commission on Monday, Gangolli, Director at Krystal Biotech, acquired stock options for 5,000 shares of KRYS. These options provide Gangolli with the right to purchase the company's stock at $137.46 per share.

Krystal Biotech shares are trading up 0.9% at $138.7 at the time of this writing on Tuesday morning. Since the current price is $138.7, this makes Gangolli's 5,000 shares worth $6,199.

Delving into Krystal Biotech's Background

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Krystal Biotech: A Financial Overview

Revenue Growth: Krystal Biotech's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 94.88%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Navigating Financial Profits:

  • Gross Margin: With a high gross margin of 94.3%, the company demonstrates effective cost control and strong profitability relative to its peers.

  • Earnings per Share (EPS): Krystal Biotech's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 1.24.

Debt Management: With a below-average debt-to-equity ratio of 0.01, Krystal Biotech adopts a prudent financial strategy, indicating a balanced approach to debt management.

Understanding Financial Valuation:

  • Price to Earnings (P/E) Ratio: Krystal Biotech's P/E ratio of 32.96 is below the industry average, suggesting the stock may be undervalued.

  • Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 12.32, Krystal Biotech's stock is perceived as being overvalued in the market, particularly in relation to sales performance.

  • EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): With a lower-than-industry-average EV/EBITDA ratio of 23.99, Krystal Biotech presents a potential value opportunity, as investors are paying less for each unit of EBITDA.

Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.

Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.

Understanding the Significance of Insider Transactions

Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.

Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.

Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.

Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.

The Insider's Guide to Important Transaction Codes

When it comes to transactions, investors tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.

Check Out The Full List Of Krystal Biotech's Insider Trades.

Insider Buying Alert: Profit from C-Suite Moves

Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

KRYS Logo
KRYSKrystal Biotech Inc
$150.150.05%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
24.86
Growth
N/A
Quality
N/A
Value
41.57
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...